[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Quoin Pharmaceuticals Ltd ADR (QNRX)

Quoin Pharmaceuticals Ltd ADR (QNRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,937
  • Shares Outstanding, K 2,008
  • Annual Sales, $ 0 K
  • Annual Income, $ -15,800 K
  • EBIT $ -17 M
  • EBITDA $ -17 M
  • 60-Month Beta 1.56
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.86

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.83
  • Number of Estimates 1
  • High Estimate $-1.83
  • Low Estimate $-1.83
  • Prior Year $-6.28
  • Growth Rate Est. (year over year) +70.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +36.92%
on 06/23/26
5.15 -13.59%
on 06/11/26
-0.39 (-8.06%)
since 05/26/26
3-Month
3.25 +36.92%
on 06/23/26
7.41 -39.95%
on 03/27/26
-3.12 (-41.18%)
since 03/26/26
52-Week
3.25 +36.92%
on 06/23/26
41.80 -89.35%
on 10/10/25
-5.28 (-54.27%)
since 06/26/25

Most Recent Stories

More News
Quoin Pharmaceuticals Receives FDA Conditional Approval of QYLEKIâ„¢ as the Proposed Brand Name for QRX003 for Netherton Syndrome

QRX003 Holds Orphan Drug Designation in the United States, the European Union, and Japan, Plus Fast Track and Rare Pediatric Disease Designations from the FDA Pivotal Phase 3 Study Expected to Initiate...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW ...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints All...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Announces Japan's MHLW Grants Orphan Drug Designation for QRX003 in Netherton Syndrome

-Designation provides regulatory and development incentives in Japan, including up to 10 years of market exclusivity upon approval- -Follows Orphan Drug Designation, Pediatric Rare Disease Designation,...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Submits IND Application for QRX003 in Peeling Skin Syndrome

-First ever IND submission for this disease, which has no current treatment or cure- -Quoin plans Phase 2 study initiation in 2H 2026- -Submission supported by positive initial clinical data...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Provides Corporate Update and Reports First Quarter 2026 Financial Results

– Filed Breakthrough Medicine Designation Application with Saudi FDA for QRX003 in Netherton Syndrome – Submitted Application to Japanese MHLW for Orphan Drug Designation (ODD) for QRX003;...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals to Announce Corporate Update and First Quarter 2026 Financial Results on Thursday, May 7, 2026

ASHBURN, Va., April 30, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan...

QNRX : 4.45 (+5.95%)
CORRECTION -- Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs

Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies in Key Indications. Company to Initiate Investigator Led Clinical Study in Pachyonychia Congenita...

QNRX : 4.45 (+5.95%)
Quoin Pharmaceuticals Provides Corporate Update and Reports Fourth Quarter and Full-Year 2025 Financial Results

– Closes Private Placement Financing of Up to $104.5 Million – Secures Orphan Drug Designations for QRX003 for Netherton Syndrome (NS) in the U.S. and Europe  – Advances Proposed Expedited...

QNRX : 4.45 (+5.95%)

Business Summary

Quoin Pharmaceuticals is a specialty pharmaceutical company focused on rare and orphan diseases. Quoin Pharmaceuticals, formerly known as Cellect Biotechnology Ltd., is based in Tel Aviv.

See More

Key Turning Points

3rd Resistance Point 5.08
2nd Resistance Point 4.78
1st Resistance Point 4.61
Last Price 4.45
1st Support Level 4.14
2nd Support Level 3.84
3rd Support Level 3.67

See More

52-Week High 41.80
Fibonacci 61.8% 27.07
Fibonacci 50% 22.52
Fibonacci 38.2% 17.98
Last Price 4.45
52-Week Low 3.25

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.